Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FOS | P01100 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723044 | 0.84 | CA2 (0.45) | CA2POLBNPC1RAB9ATSHR | |
| SCHEMBL5058089 | 0.82 | NPC1 (0.38) | CA2POLBNPC1RAB9ATSHR | |
| SCHEMBL19578912 | 0.82 | PTGS2 (0.52) | CA2POLBTSHRALDH1A1GAA | |
| SCHEMBL28170408 | 0.81 | CA2 (0.68) | CA2POLBNPC1RAB9AALDH1A1 | |
| SCHEMBL119395 | 0.81 | CA2 (0.68) | CA2POLBNPC1RAB9AALDH1A1 | |
| SCHEMBL29997296 | 0.81 | CA2 (0.68) | CA2POLBNPC1RAB9AALDH1A1 | |
| SCHEMBL16959158 | 0.81 | HTT (0.47) | POLBNPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL15849814 | 0.80 | CYP4F2 (0.39) | CA2POLBNPC1RAB9ATSHR | |
| SCHEMBL17913155 | 0.80 | KDM4E (0.48) | CA2TSHRALDH1A1GAANFKB1 | |
| SCHEMBL4217006 | 0.79 | CSNK2A1 (0.42) | POLBNPC1RAB9AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-111542516-B | IRAK4 inhibitors and uses thereof | 新标立亚医疗有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20200385370-A1 | APPARATUS FOR REMOVING BAD ODOR FROM TOILET | SYNBLIA THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385370-A1 | APPARATUS FOR REMOVING BAD ODOR FROM TOILET | SYNBLIA THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2020-12-03 | — | — | US | disclosed |
| CN-106458912-B | Bicyclic fused heteroaryl or aryl compounds and their use as IRAK4 mimetics | 辉瑞公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110294756-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-01 | — | — | US | disclosed |
| US-20110294756-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-01 | — | — | US | disclosed |
| US-20110257156-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-20 | — | — | US | disclosed |
| US-20110257156-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-20 | — | — | US | disclosed |
| WO-2010056849-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056722-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054078-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| US-6825181-B1 | ORALLY ADMINISTRATED TO EXHIBIT A STRONG ANTICOAGULANT EFFECT BY INHIBITING ACTIVATED BLOOD- COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| EP-1065200-A1 | AMINOISOQUINOLINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257156-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CA2 3225/4885POLB 1910/4885NPC1 531/4885 |
| US-20110294756-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | CA2 3413/4885POLB 2140/4885NPC1 680/4885 |
| US-20200385370-A1 | APPARATUS FOR REMOVING BAD ODOR FROM TOILET | IRAK4, IRAK1, IRAK2 | CA2 4043/4885POLB 1437/4885NPC1 3497/4885 |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CA2 2381/4885POLB 1448/4885NPC1 690/4885 |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | CA2 3630/4885POLB 2014/4885NPC1 247/4885 |
| US-10793579-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | CA2 3630/4885POLB 2014/4885NPC1 247/4885 |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | CA2 2479/4885POLB 2761/4885NPC1 2914/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | CA2 2479/4885POLB 2761/4885NPC1 2914/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | CA2 3630/4885POLB 2014/4885NPC1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.